Ganesh R. Koshre
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
23
Citations
55
Est. group size
~12
Recurring co-author estimate
Active years
6
Publishing since 2021
Ganesh R. Koshre's research centers on a specific molecular signaling pathway (S100A7/RAGE/STAT3) involved in breast cancer growth and immune evasion, with recent work exploring how blocking this pathway might help immunotherapy work better against metastatic breast cancer. The publication record is heavily concentrated in one recent cluster of related papers and their associated supplementary data files, rather than a long, diverse publication history.
Publication activity appears minimal or absent for most of the last decade, with an apparent sharp concentrated burst of outputs (including many supplementary data files tied to a single study) recorded in 2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract 7463: Targeting S100A7/RAGE-driven Stat3/Serpin-E1 signaling for immunotherapy in metastatic breast cancer
Cancer Research · 2026
- Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression
Breast Cancer Research · 2026
- Additional file 4 of Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression
Figshare · 2026
- Additional file 1 of Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression
Figshare · 2026
- Additional file 7 of Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression
Figshare · 2026
- Additional file 4 of Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression
Figshare · 2026
- Additional file 8 of Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression
Figshare · 2026
- Additional file 6 of Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression
Figshare · 2026
- Additional file 5 of Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression
Figshare · 2026
- Additional file 7 of Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression
Figshare · 2026
- Additional file 6 of Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression
Figshare · 2026
- Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression
Figshare · 2026
- Additional file 3 of Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression
Figshare · 2026
- Additional file 1 of Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression
Figshare · 2026
- Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression
Figshare · 2026
- Figshare×18
- Wiley Interdisciplinary Reviews - RNA×1
- International Journal of Molecular Sciences×1
- Thyroid×1
- Cancer Research×1
- Pratyusha Ghanta
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Manish Charan
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Dinesh K. Ahirwar
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Ramesh K. Ganju
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Sanjay Mishra
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile